Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
Esophageal Cancer|Gastric Cancer
DRUG: Cetuximab,Paclitaxel, Carboplatin
Reponse Rate at Time of Surgery by Tissue, pathologic complete response rate at surgery, within 30 days of last treatment
Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach., CTCAE version 3: grade 2 and 3 rash. This is reported as it was the most common toxicity., baseline, then during treatment, about 5 weeks through 30 days post treatment.
The primary objective of this phase II trial is to estimate the rate of complete pathologic response as determined by surgical resection or post treatment endoscopy (for patients not undergoing resection) for the treatment regimen being tested. With a total accrual of 28 evaluable patients.